Since the beginning of the 21st century, John has been at the forefront of challenging the ideology of pharmaceutical innovation. In particular, he has consistently drawn attention to the fact that within the orthodox economics of innovation, much of ‘innovation studies’, and the conventions of pharmaceutical innovation accounting by governments, the fact that a drug product is a pharmaceutical innovation does not necessarily mean that it offers any therapeutic advance over existing medicines on the market, let alone that it is a therapeutic breakthrough. In fact, most pharmaceutical product innovations offer little or no clinically significant therapeutic advance over medicines already available on the market. John has also empirically investigated the ideological process of pharmaceutical innovation in relation to ‘promissory science’ in claims about the efficacy of new drugs in development (e.g. in clinical trials) are pushed to the very limit of scientific credibility and sometimes beyond. This theme is exemplified in the following publications:
John Abraham and Courtney Davis Unhealthy Pharmaceutical Regulation: Innovation, Politics and Promissory Science, 348pp, Palgrave, 2013.
John Abraham and Courtney Davis (2007) ‘Interpellative sociology of pharmaceuticals: problems and challenges for innovation and regulation in the 21st century’ Technology Analysis and Strategic Management 19: 387-402.
John Abraham and Courtney Davis (2011) ‘Re-thinking innovation accounting in pharmaceutical regulation: a case study in the deconstruction of “therapeutic advance” and “therapeutic breakthrough”’ Science, Technology & Human Values: the official journal of the Society for Social Studies of Science 36(4): 791-815.
John Abraham and Gowree Balendran (2026) ‘Synthetic Certainization in medical controversy: Evidence synthesis, NICE recommendations and the drug-device complex in stroke prevention’ Journal of Critical Public Health 3: 38-56.
Jonathan Guillemot, John Abraham and Anthea Tinker, A (2025) ‘Understanding trends in osteoporosis drug prescribing in England and France’ Frontiers in Medicine (13 January 2025), pp1-17. Doi 10.3389/fmed.2024.1454150
John Abraham and Courtney Davis (2011) ‘Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation’ Sociology of Health & Illness, 33(4): 731-47.
John Abraham and Courtney Davis (2012) ‘The political dynamics of citizenship, innovation, and regulation in pharmaceutical governance’ Innovation: The European Journal of Social Science Research 25(4): 462-78.
John Abraham and Courtney Davis (2011) ‘The socio-political roots of pharmaceutical uncertainty in the evaluation of “innovative” diabetes drugs in the EU and the US’ Social Science & Medicine, 72: 1574-81.
John Abraham (2002) ‘A social science framework for the analysis of health technology regulation: the risks and benefits of innovative pharmaceuticals in a comparative context’ Health, Risk & Society 4: 305-24.
John Abraham and Tim Reed (2002) ‘Progress, innovation and regulatory science: the politics of international standard-setting’ Social Studies of Science 32: 337-69.
John Abraham, Paul Martin, Courtney Davis, and Alison Kraft (2006) ‘Understanding the “productivity crisis” in the pharmaceutical industry: over-regulation or lack of innovation?’ in (ed.) A. Webster, New Technologies in Health Care, pp. 177-93, Palgrave.
John Abraham (2004) ‘Innovation, expectation and regulation: industry, public and regulatory understanding of innovation in contemporary pharmaceutical markets’, Healthy Innovation, University of Manchester.
John Abraham (2006) ‘Pharmaceutical Innovation: Key Problems and Challenges’ Science Policy Research Unit 40th Anniversary.
John Abraham (2006) ‘Reconceptualising Pharmaceutical Innovation in terms of Need and Justice: What could it mean?’ Regents College London.